05:13 PM EST - BioVaxys Technology Corp : Announced positive findings from a Phase 2 clinical study evaluating maveropepimut-S (MVP-S) in combination with pembrolizumab and low-dose cyclophosphamide in patients with advanced or metastatic bladder cancer. These results build on the Company’s recent Phase 1B/2 data in advanced ovarian cancer and further validate the potential of MVP-S to enhance checkpoint inhibitor activity across multiple solid tumor indications. BioVaxys Technology Corp
shares C.BIOV are trading up one cent at $0.21.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=BIOV%3ACC&qmodStoryID=6505179275707541
